Screener
IDNA vs PBE
iShares Genomics Immunology and Healthcare ETF vs Invesco Biotechnology & Genome ETF
Key differences
- IDNA costs 0.11% less per year.
- Over the last 3 years, PBE has delivered higher annualized returns.
- PBE has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| IDNA | PBE | |
|---|---|---|
| Annual cost (TER) | 0.47% | 0.58% |
| Fund size (AUM) | $160M | $247M |
| Since | 2019 | 2005 |
| Dividend yield | 1.05% | 1.09% |
| Asset class | equity | equity |
| Region | — | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +49.2% | +34.1% |
| CAGR 3Y | +8.0% | +10.3% |
| CAGR 5Y | -7.5% | +3.3% |
| Sharpe 3Y | 0.29 | 0.41 |
| Volatility 1Y | 24.43% | 18.63% |
| Max drawdown | -68.26% | -37.84% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to IDNA and PBE
Explore further